Immunome, Inc. (IMNM) Financial Statements
Immunome, Inc. (IMNM) reported trailing twelve-month revenue of $0 (up 18804.0% year on year) and net income of -$254.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$219.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMNMImmunome, Inc.Follow IMNM — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 14.0 | 9.0 | 6.9 | 0.0 | |
| Research & development | 23.1 | 129.5 | 177.3 | 206.2 | |
| Operating income | -109.5 | -305.8 | -224.1 | -270.5 | |
| Pre-tax income | -106.8 | -293.0 | -212.4 | -254.3 | |
| Income tax | 0.0 | 0.0 | 0.0 | — | |
| Net income | -106.8 | -293.0 | -212.4 | -254.3 | |
| Diluted EPS ($) | -5.38 | -5.00 | -2.43 | -2.25 | |
| Diluted shares (mn) | 19.8 | 58.6 | 87.4 | — |
USD millions · SEC XBRL
Immunome, Inc. — questions
- What is Immunome, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 18804.0% year on year, from its 10-Q and 10-K filings.
- What is Immunome, Inc.'s net income?
- -$254.3M over the twelve months to 2026-06-30.
- What is Immunome, Inc.'s free cash flow?
- -$219.1M over the twelve months to 2026-06-30.
- What are Immunome, Inc.'s diluted earnings per share?
- $-2.25 over the twelve months to 2026-06-30.
Every figure on this page comes from Immunome, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.